Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

Nuevolution Announces New Research Collaboration with Big Pharma

Published: Tuesday, September 01, 2009
Last Updated: Tuesday, September 01, 2009
Bookmark and Share
Partnership to use Nuevolution's Chemetics® technology for lead discovery.

Nuevolution A/S has announced that it has entered into a drug discovery collaboration with Novartis.

During the collaboration, Nuevolution will apply its proprietary Chemetics® drug discovery technology to identify novel small molecule leads against drug targets of interest to Novartis. The Chemetics® platform uses DNA labeling to allow fragment-based drug screening at an unprecedented scale.

Nuevolution will screen its multi-million member diverse fragment based screening libraries for hit identification. Through the design, synthesis and screening of target focused Chemetics® follow-up libraries, the parties will also work together to perform hit-to-lead optimization.

Under the terms of the agreement, Novartis will provide Nuevolution with an upfront payment, research funding, and milestone payments as candidate molecules progress through preclinical and clinical development and onto the market.

In addition, Nuevolution is eligible to receive royalties on the commercial sales of approved products. Further financial details were not disclosed.

“We are delighted that Novartis has elected to enter this collaboration with Nuevolution” said Alex Gouliaev, CEO of Nuevolution A/S, and continued: “We look forward to an exciting and fruitful outcome of the collaboration.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Novartis Provides Drug Candidate Compounds to TB Alliance
Exclusive worldwide license from Novartis includes a novel class of drugs that is active against drug sensitive and multi-resistant strains of tuberculosis.
Wednesday, August 20, 2014
Novartis Announces Portfolio Transformation
Company launches a major overhaul of its business, unveiling a series of multibillion-dollar deals with GSK and Eli Lilly.
Wednesday, April 23, 2014
FORMA Announces Collaboration with Novartis to Develop Inhibitors of Protein-Protein Interactions
FORMA will leverage its expertise to develop inhibitors for an undisclosed protein-protein interaction target in the field of oncology.
Tuesday, January 13, 2009
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Long-Sought Protein Sensor for the ‘Sixth Sense’ Discovered
In a study led by scientists from The Scripps Research Institute (TSRI)the sensor protein for propioception has been identified.
New Anti-Malarial Drug Screening Model
University of South Florida researchers demonstrate novel chemogenomic profiling to identify drug targets for the most lethal strain of malaria.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
New, Better Test for Prostate Cancer
A study from Karolinska Institutet shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
Giant Molecules Inhibit Ebola Infection
European researchers have designed a "giant" molecule formed by thirteen fullerenes covered by carbohydrates which, by blocking this receptor, are able to inhibit the cell infection by an artificial ebola virus model.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos